Trial Profile
A prospective bioequivalence trial to evaluate the pharmacokinetics of Lisdexamfetamine (Vyvanse) in healthy adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Lisdexamfetamine (Primary) ; Lisdexamfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Pharmacokinetics
- 16 Jul 2019 Results published in the FDA Document
- 10 Jul 2019 According to a Takeda media release, Health Canada's authorization of chewable tablets is based on this study.
- 18 Apr 2016 New trial record